AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

曾经的“不可成药”靶点，如今各大药企眼中的香饽饽，KRAS的华丽转身从2021年安进的Sotorasib登场开始。 随后，国内药企的反应极其迅速，纷纷快速 ...

Since the discovery of RAS gene mutations in DNA from human tumours around 40 years ago, KRAS has emerged as the most frequently mutated oncogene in human cancer, particularly in pancreatic ...

Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million Chinese yuan ($21 million) for rights to a near-approval inhibitor of ...

加科思8月30日公告称，KRAS G12C抑制剂Glecirasib与SHP2抑制剂JAB-3312的中国区权益对外授权（out license）给艾力斯，总交易金额近10亿，其中包括1.5亿元首 ...

Research into targeted TP53 therapies is ongoing. The KRAS mutation is found in about 30% of all NSCLCs. It’s more common in people who smoke. The outlook for people with this type of mutation ...

Jacobio is a very outstanding innovative biotech company that has successfully developed and promoted a number of excellent products with great clinical value, including the KRAS G12C inhibitor ...